



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Antidiabetic agent 5

Cat. No.:	HY-161429
CAS No.:	2152667-21-3
Molecular Formula:	C ₁₇ H ₁₅ N ₃ O ₄ S
Molecular Weight:	357.38
Target:	Amylases; Glucosidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α -glucosidase and α -amylase with IC ₅₀ values of 3.91, 8.89 μ M, respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes ^[1] .								
IC₅₀ & Target	IC ₅₀ : 3.91 μ M (α -glucosidase); 8.89 μ M (α -amylase) ^[1]								
In Vivo	<p>Antidiabetic agent 5 (compound S1) α-glucosidase Antidiabetic agent 5 α-amylase (α-glucosidase) α-amylase IC₅₀ 3.91 8.89 μM Antidiabetic agent 5 II ^[1]</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>26-33 g, BALB/c mice (diabetes)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>3.9, 7.8 mg/kg</td> </tr> <tr> <td>Administration:</td> <td></td> </tr> <tr> <td>Result:</td> <td>Exhibited a good biochemical profile with lower sugar level (110–115 mg/dL), increased insulin level (25–30 μM/L), and low level of cholesterol (85 mg/dL) and creatinine (0.6 mg/dL) in blood.</td> </tr> </table>	Animal Model:	26-33 g, BALB/c mice (diabetes) ^[1]	Dosage:	3.9, 7.8 mg/kg	Administration:		Result:	Exhibited a good biochemical profile with lower sugar level (110–115 mg/dL), increased insulin level (25–30 μ M/L), and low level of cholesterol (85 mg/dL) and creatinine (0.6 mg/dL) in blood.
Animal Model:	26-33 g, BALB/c mice (diabetes) ^[1]								
Dosage:	3.9, 7.8 mg/kg								
Administration:									
Result:	Exhibited a good biochemical profile with lower sugar level (110–115 mg/dL), increased insulin level (25–30 μ M/L), and low level of cholesterol (85 mg/dL) and creatinine (0.6 mg/dL) in blood.								

REFERENCES

[1]. Taj S, et al. The antihyperglycemic potential of pyrazolobenzothiazine 1, 1-dioxide novel derivative in mice using integrated molecular pharmacological approach. Sci Rep. 2024 Apr 2;14(1):7746.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA